Posted by Michael Wonder on 11 Oct 2022
Scotland backs three new uses for MSD’s Keytruda
11 October 2022 - Scotland has become the first country in the UK to back NHS funding for the use of Merck/MSD’s Keytruda in combination with Eisai’s Lenvima as a treatment for advanced or recurrent endometrial cancer.
The SMC gave the go-ahead to the regimen based on data from the KEYNOTE-775 trial, which showed that the duo can increase survival time for patients and may improve quality of life by reducing the symptom burden compared to standard chemotherapy.
